Skip to main content
BioCentury Conference Center

SciBX Summit 2013 Panelists & Respondents

Non-Coding RNAs as Tools and Targets Panelists

Organized by

BioCentury

 

Nature Publishing Group

 
2013 Sponsors
 
2013 Sponsors
 
2013 Advisory
Council Members

 
2013 Advisory Council

Dr. David Corey, Professor, UT Southwestern Medical Center at Dallas

LinkedIn

 

Dr. Jean-François Formela, Partner, Atlas Venture

LinkedIn

 

Dr. Art Krieg, President & CEO, RaNA Therapeutics Inc.

LinkedIn

Art Krieg

Dr. Arthur Levin, EVP, miRagen Therapeutics

LinkedIn

Art Krieg

Dr. Laura Sepp-Lorenzino, Executive Director, RNA Therapeutics, Merck & Co. Inc.

LinkedIn

Laura Sepp-Lorenzino
   

New Models in Neurological Diseases Panelists

Dr. Daniela Brunner, SVP Behavioral Research and Development, PsychoGenics Inc.

LinkedIn

 

Dr. Magali Haas, Chief Science & Technology Officer, One Mind

LinkedIn

Magali Haas

Dr. Ken Rhodes, VP of Neurology Research, Biogen Idec Inc.

LinkedIn

Ken Rhodes

Dr. Mustafa Sahin, Associate Professor, Children's Hospital Boston

LinkedIn

 

Dr. Mriganka Sur, Professor of Neuroscience; Director, Simons Center for the Social Brain, MIT

LinkedIn

 
   

CAR-Based Cellular Therapies Panelists

Dr. Stewart Abbot, Executive Director, Celgene

LinkedIn

Panelist Photo

Dr. Gwen Binder-Scholl, EVP, Adaptimmune LLC

LinkedIn

Panelist Photo

Dr. Renier Brentjens, Physician, Memorial Sloan-Kettering Cancer Center

LinkedIn

 

Dr. Aya Jakobovits, President & CEO, Kite Pharma Inc.

LinkedIn

 

Dr. Tom Schuetz, Consultant, Atlas Venture

 

 
   

Respondent

Dr. Madhusudan Peshwa, EVP of Cellular Therapies, MaxCyte Inc.

LinkedIn

Panelist Photo
   

Epigenetics' Second Wind Panelists

Dr. James Audia, Chief Scientific Officer, Constellation Pharmaceuticals Inc.

LinkedIn

Panelist Photo

Dr. Bruce Booth, Partner, Atlas Venture

LinkedIn

Bruce Booth

Dr. Charles Roberts, Associate Professor, Harvard Medical School

 

 

Dr. Stuart Schreiber, Director, Center for the Science of Therapeutics, Broad Institute

 

 

Dr. Jesse Smith, Executive Director of Biological Sciences, Epizyme Inc.

LinkedIn

 

Dr. Peter Tummino, Senior Director, GlaxoSmithKline

LinkedIn

Peter Tummino
   

Respondents

Dr. Simon Kerry, CEO, Karus Therapeutics Ltd.

LinkedIn

Panelist Photo

Donald McCaffrey, President & CEO, Zenith Epigenetics Corp.